Literature DB >> 21135582

Relation between cardiovascular risk factors and coronary microvascular dysfunction in cardiac syndrome X.

Alfonso Sestito1, Gaetano A Lanza, Antonio Di Monaco, Priscilla Lamendola, Giulia Careri, Pierpaolo Tarzia, Gaetano Pinnacchio, Irma Battipaglia, Filippo Crea.   

Abstract

BACKGROUND: The causes of coronary microvascular dysfunction (CMVD) in patients with cardiac syndrome X (CSX) are largely unknown. Common cardiovascular risk factors (CVRFs) and increased markers of inflammation have been associated with CMVD in some studies, but their role in determining CMVD in CSX patients remains poorly known. METHODS AND
RESULTS: We studied 71 CSX patients (56 ± 9 years, 23 men) and 20 healthy volunteers (52 ± 7 years, nine men). Using transthoracic Doppler echocardiography, coronary microvascular vasodilator function was assessed in the left anterior descending coronary artery as the ratio of diastolic coronary blood flow (CBF) velocity at peak intravenous adenosine administration and during cold pressor test (CPT) to the respective basal CBF velocity values. Common CVRFs tended to be more frequent and C-reactive protein (CRP) levels were higher (P < 0.001) in CSX patients than in controls. Both CBF responses to adenosine (2.05 ± 0.6 vs. 2.92 ± 0.9, P < 0.001) and to CPT (1.71 ± 0.6 vs. 2.42 ± 0.7, P < 0.001) were lower in CSX patients than in controls. The differences between the two groups in CBF response to adenosine and in CBF response to CPT remained highly significant (P < 0.01 for both) after adjustment for all CVRFs, including serum CRP levels.
CONCLUSION: In CSX patients, both endothelium-dependent and endothelium-independent CMVD cannot be reliably predicted by CVRFs (including serum CRP levels), alone or in combination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21135582     DOI: 10.2459/JCM.0b013e3283406479

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  9 in total

Review 1.  Diagnosis of coronary microvascular dysfunction - Present status.

Authors:  S R Mittal
Journal:  Indian Heart J       Date:  2015-11-06

2.  Coronary microvascular dysfunction in patients with acute coronary syndrome and no obstructive coronary artery disease.

Authors:  Antonio De Vita; Laura Manfredonia; Priscilla Lamendola; Angelo Villano; Salvatore Emanuele Ravenna; Antonio Bisignani; Giampaolo Niccoli; Gaetano Antonio Lanza; Filippo Crea
Journal:  Clin Res Cardiol       Date:  2019-03-29       Impact factor: 5.460

Review 3.  Etiopathogenesis of microvascular angina: caveats in our knowledge.

Authors:  S R Mittal
Journal:  Indian Heart J       Date:  2014-11-04

4.  Coronary autoregulation is abnormal in syndrome X: insights using myocardial contrast echocardiography.

Authors:  Diana Rinkevich; Todd Belcik; Nandita C Gupta; Elizabeth Cannard; Nabil J Alkayed; Sanjiv Kaul
Journal:  J Am Soc Echocardiogr       Date:  2013-01-11       Impact factor: 5.251

Review 5.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

Review 6.  Coronary microvascular dysfunction in women: an overview of diagnostic strategies.

Authors:  Sujith Kuruvilla; Christopher M Kramer
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-11

Review 7.  Angina Pectoris and Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease: Role of Diagnostic Tests.

Authors:  Gaetano Antonio Lanza
Journal:  Curr Cardiol Rep       Date:  2016-02       Impact factor: 2.931

8.  Association of Inflammation and Endothelial Dysfunction with Coronary Microvascular Resistance in Patients with Cardiac Syndrome X.

Authors:  Ming Long; Zhibin Huang; Xiaodong Zhuang; Zena Huang; Yue Guo; Xinxue Liao; Chufan Luo
Journal:  Arq Bras Cardiol       Date:  2017-10-19       Impact factor: 2.000

Review 9.  Obesity Related Coronary Microvascular Dysfunction: From Basic to Clinical Practice.

Authors:  K Selthofer-Relatić; I Bošnjak; A Kibel
Journal:  Cardiol Res Pract       Date:  2016-03-22       Impact factor: 1.866

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.